In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opexa Therapeutics, Inc.

http://www.opexatherapeutics.com

Latest From Opexa Therapeutics, Inc.

Unity’s UBX1325 Faces Uncertain Path Forward In AMD, But DME Still Looks Promising

The company said the Phase II ENVISION study of the drug in wet age-related macular degeneration did not show non-inferiority to Eylea, leaving it with an uncertain path forward in that indication.

Clinical Trials Business Strategies

Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances

Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

Scrip Asks Research & Development

From Science To Commercialization: How Genexine Is Making The Shift

Genexine CEO Neil Warma talks to Scrip in this audio interview about a wide range of topics, including key strategy changes, ambitions to become a leading global biopharma, as well as challenges he has faced since joining the Korean biotech.

South Korea ImmunoOncology

Pfizer Takes First Small Step Into Longevity Field With Gero Collaboration

Interest in longevity and anti-aging is gathering momentum, and Pfizer has dipped its toe in the water with an early-stage drug discovery partnership.

Deals Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register